Curcumin, a
phytochemical agent in the spice turmeric, has received increasing attention for its anticancer, anti-inflammatory and
antioxidant properties. However, application of
curcumin has been limited due to its insolubility in water and poor bioavailability both clinically and experimentally. In addition, the protective effects and mechanisms of
curcumin in
eye diseases have been poorly studied. In the present study, we synthesized a
curcumin analog, 1, 5-bis (2-trifluoromethylphenyl)-1, 4-pentadien-3-one (C3), which displayed improved protective effect against
acrolein-induced toxicity in a human
retinal pigment epithelial cell line (ARPE-19). At 5 μM,
curcumin completely protected against
acrolein-induced cell oxidative damage and preserved GSH levels and mitochondrial function. Surprisingly, C3 displayed a complete protective effect at 0.5 μM, which was much more efficient than
curcumin. Both 0.5 μM C3 and 5 μM
curcumin induced Nrf2 nuclear translocation and Nrf2 target genes transcription similarly. Experiments using Nrf2
siRNA showed that the protective effects of
curcumin and C3 were eliminated by Nrf2 knockdown. Additionally, both
curcumin and C3 activated the PI3/Akt pathway, however, Nrf2 activation was independent of this pathway, and therefore, we hypothesized that both
curcumin and C3 activated phase II
enzymes via directly disrupting the Nrf2/Keap1 complex and promoting Nrf2's nuclear translocation. Since
acrolein challenge of ARPE-19 cells has been used as a model of smoking and
age-related macular degeneration (AMD), we concluded that the
curcumin analog, C3, may be a more promising
drug candidate for its potential application for the prevention and treatment of
eye diseases, such as AMD.